Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CCL5

CCL5

Basics

Aliases:
This biomarker is also known as:
  • C-C motif chemokine 5,
  • T cell-specific protein P228,
  • EoCP,
  • RANTES,
  • MGC17164,
  • small inducible cytokine A5 (RANTES),
  • SISd,
  • small-inducible cytokine A5,
  • SIS-delta,
  • small inducible cytokine subfamily A (Cys-Cys), member 5,
  • SCYA5,
  • T-cell specific protein p288,
  • eosinophil chemotactic cytokine,
  • beta-chemokine RANTES,
  • Small-inducible cytokine A5,
  • Eosinophil chemotactic cytokine,
  • eoCP,
  • t cell-specific protein P228,
  • T-cell-specific protein RANTES,
  • TCP228,
  • chemokine (C-C motif) ligand 5,
  • regulated upon activation, normally T-expressed, and presumably secreted,
  • D17S136E,

View in BioMuta

Description…

From NCBI Gene: This gene is one of several chemokine genes clustered on the q-arm of chromosome 17. Chemokines form a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of the N-terminal cysteine residues of the mature peptide. This chemokine, a member of the CC subfamily, functions as a chemoattractant for blood monocytes, memory T helper cells and eosinophils. It causes the release of histamine from basophils and activates eosinophils. This cytokine is one of the major HIV-suppressive factors produced by CD8+ cells. It functions as one of the natural ligands for the chemokine receptor chemokine (C-C motif) receptor 5 (CCR5), and it suppresses in vitro replication of the R5 strains of HIV-1, which use CCR5 as a coreceptor. Alternative splicing results in multiple transcript variants that encode different isoforms. [provided by RefSeq, Jul 2013]

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: CCL5

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Curated

Overview

The chemokine CCL5 (RANTES), a major monocyte chemoattractant expressed by breast tumor cells, has been implicated in the progression of breast cancer.

Performance Comment

CCL5 (RANTES) was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.